Literature DB >> 23881877

Human psychobiology of MDMA or 'Ecstasy': an overview of 25 years of empirical research.

Andrew C Parrott1.   

Abstract

AIMS: This paper aimed to review how scientific knowledge about the human psychobiology of MDMA has developed over time.
METHODS: In this paper, the empirical findings from earlier and later studies will be reviewed.
RESULTS: When MDMA was a 'novel psychoactive substance', it was not seen as a drug of abuse, as it displayed loss of efficacy. However, recreational users display a unique pattern of increasing doses, deteriorating cost-benefit ratios, and voluntary cessation. MDMA increases body temperature and thermal stress, with cortisol levels increased by 800% in dance clubbers. It can be extremely euphoric, although negative moods are also intensified. MDMA causes apoptosis (programmed cell death) and has been investigated for cancer therapy because of its anti-lymphoma properties. Recreational users show deficits in retrospective memory, prospective memory, higher cognition, problem solving, and social intelligence. Basic cognitive skills remain intact. Neuroimaging studies show reduced serotonin transporter levels across the cerebral cortex, which are associated with neurocognitive impairments. Deficits also occur in sleep architecture, sleep apnoea, complex vision, pain, neurohormones, and psychiatric status. Ecstasy/MDMA use during pregnancy leads to psychomotor impairments in the children.
CONCLUSIONS: The damaging effects of Ecstasy/MDMA are far more widespread than was realized a few years ago, with new neuropsychobiological deficits still emerging.
Copyright © 2013 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Ecstasy; MDMA; SERT; memory; neurotoxicity; serotonin

Mesh:

Substances:

Year:  2013        PMID: 23881877     DOI: 10.1002/hup.2318

Source DB:  PubMed          Journal:  Hum Psychopharmacol        ISSN: 0885-6222            Impact factor:   1.672


  36 in total

1.  Repeated Administration of 3,4-Methylenedioxymethamphetamine (MDMA) Elevates the Levels of Neuronal Nitric Oxide Synthase in the Nigrostriatal System: Possible Relevance to Neurotoxicity.

Authors:  Giulia Costa; Micaela Morelli; Nicola Simola
Journal:  Neurotox Res       Date:  2018-04-09       Impact factor: 3.911

2.  Prevalence of reagent test-kit use and perceptions of purity among ecstasy users in an electronic dance music scene in New York City.

Authors:  Joseph J Palamar; Monica J Barratt
Journal:  Drug Alcohol Rev       Date:  2018-12-21

3.  An examination of sociodemographic correlates of ecstasy use among high school seniors in the United States.

Authors:  Joseph J Palamar; Dimitra Kamboukos
Journal:  Subst Use Misuse       Date:  2014-06-23       Impact factor: 2.164

Review 4.  Clinical applications of hallucinogens: A review.

Authors:  Albert Garcia-Romeu; Brennan Kersgaard; Peter H Addy
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

Review 5.  The effects of ecstasy on neurotransmitter systems: a review on the findings of molecular imaging studies.

Authors:  Yosta Vegting; Liesbeth Reneman; Jan Booij
Journal:  Psychopharmacology (Berl)       Date:  2016-08-28       Impact factor: 4.530

6.  Self-Reported Ecstasy/MDMA/"Molly" Use in a Sample of Nightclub and Dance Festival Attendees in New York City.

Authors:  Joseph J Palamar; Patricia Acosta; Danielle C Ompad; Charles M Cleland
Journal:  Subst Use Misuse       Date:  2016-09-23       Impact factor: 2.164

7.  Alterations to global but not local motion processing in long-term ecstasy (MDMA) users.

Authors:  Claire White; John Brown; Mark Edwards
Journal:  Psychopharmacology (Berl)       Date:  2014-01-19       Impact factor: 4.530

8.  Separating the agony from ecstasy: R(-)-3,4-methylenedioxymethamphetamine has prosocial and therapeutic-like effects without signs of neurotoxicity in mice.

Authors:  Daniel W Curry; Matthew B Young; Andrew N Tran; Georges E Daoud; Leonard L Howell
Journal:  Neuropharmacology       Date:  2017-10-06       Impact factor: 5.250

9.  Psychiatric profiles of mothers who take Ecstasy/MDMA during pregnancy: reduced depression 1 year after giving birth and quitting Ecstasy.

Authors:  John J D Turner; Andrew C Parrott; Julia Goodwin; Derek G Moore; Sarah Fulton; Meeyoung O Min; Lynn T Singer
Journal:  J Psychopharmacol       Date:  2013-12-10       Impact factor: 4.153

10.  Developmental outcomes of 3,4-methylenedioxymethamphetamine (ecstasy)-exposed infants in the UK.

Authors:  Lynn T Singer; Derek G Moore; Meeyoung O Min; Julia Goodwin; John J D Turner; Sarah Fulton; Andrew C Parrott
Journal:  Hum Psychopharmacol       Date:  2015-07       Impact factor: 1.672

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.